Clinical Trial · NCT06122584

Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer

Overview

This study assess the Diagnostic Performance of \[18F\]PSMA-1007 PET/CT Imaging in Patients with Newly-Diagnosed High-Risk or Very-High-Risk Prostate Cancer

Sponsor

Advanced Biochemical Compounds

Phase

Phase 3

Contacts

Alexander Hoepping, Dr. (CONTACT)

cd@abx.de

+49 3528 4041 60

ClinicalTrials.gov

NCT06122584

Drug / Compound

PSMA-1007

Isotope(s):

Target(s):

PSMA

Ligand Class: Small Molecules

Eligibility

Inclusion

The patient has at least high-risk disease as defined by the NCCN guidelines (version 1.2023). That is, the presence of any one or more of the following:
Clinical category T3a or greater,
Serum PSA level greater than 20 ng/ml.
The patient has newly diagnosed, biopsy-proven, clinically localized prostate adenocarcinoma, and curative prostatectomy with extended pelvic lymph node dissection is his preferred course of treatment.
Overall ISUP grade group 4 or 5,

Exclusion

Patients for whom radical prostatectomy is not clinically appropriate or the patient is otherwise unlikely to undergo radical prostatectomy with extensive pelvic lymph node dissection.